• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of CYP3A4 Genotype on Voriconazole Exposure.

作者信息

Duflot Thomas, Schrapp Aurélien, Bellien Jérémy, Lamoureux Fabien

机构信息

Rouen University Hospital, Department of Pharmacology - Toxicology and Pharmacogenetics, Rouen, France.

Normandie University, UNIROUEN, Inserm U1096, Rouen, France.

出版信息

Clin Pharmacol Ther. 2018 Feb;103(2):185-186. doi: 10.1002/cpt.809. Epub 2017 Aug 29.

DOI:10.1002/cpt.809
PMID:28786228
Abstract
摘要

相似文献

1
Impact of CYP3A4 Genotype on Voriconazole Exposure.细胞色素P450 3A4（CYP3A4）基因多态性对伏立康唑血药浓度的影响
Clin Pharmacol Ther. 2018 Feb;103(2):185-186. doi: 10.1002/cpt.809. Epub 2017 Aug 29.
2
Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole".对《CYP3A4基因分型对伏立康唑暴露的影响：CYP3A4*22对伏立康唑代谢贡献的新见解》的回应
Clin Pharmacol Ther. 2018 Feb;103(2):187. doi: 10.1002/cpt.811. Epub 2017 Nov 16.
3
Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped.伏立康唑的药物遗传学：CYP2C19以及CYP3A4均需进行基因分型。
Clin Pharmacol Ther. 2017 Aug;102(2):189. doi: 10.1002/cpt.662. Epub 2017 May 26.
4
Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole.对《伏立康唑的药物遗传学：CYP2C19以及CYP3A4均需进行基因分型》的回应——CYP3A4和CYP3A5基因多态性在伏立康唑临床药代动力学中的作用
Clin Pharmacol Ther. 2017 Aug;102(2):190. doi: 10.1002/cpt.681. Epub 2017 Apr 29.
5
Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.药物遗传学可能会影响炎症对伏立康唑谷浓度的影响。
Pharmacogenomics. 2017 Aug;18(12):1119-1123. doi: 10.2217/pgs-2017-0054. Epub 2017 Jul 26.
6
A genetic score combining CYP450 2C19 and 3A4 genotypes to predict voriconazole plasma exposure?一种结合CYP450 2C19和3A4基因型来预测伏立康唑血药浓度的基因评分？
Int J Antimicrob Agents. 2016 Aug;48(2):221-2. doi: 10.1016/j.ijantimicag.2016.05.002. Epub 2016 Jun 7.
7
Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.细胞色素P450 3A4和非遗传因素对不同细胞色素P450 2C19基因型血液病患者伏立康唑初始血清谷浓度的影响。
Xenobiotica. 2017 Dec;47(12):1121-1129. doi: 10.1080/00498254.2016.1271960. Epub 2017 Jan 3.
8
Association of , and polymorphisms and voriconazole plasma concentrations in Uygur pediatric patients.维吾尔族儿科患者中 、 和 基因多态性与伏立康唑血药浓度的相关性
Pharmacogenomics. 2023 Feb;24(3):141-151. doi: 10.2217/pgs-2022-0159. Epub 2023 Jan 31.
9
Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.CYP2C19 基因型对伏立康唑暴露的影响以及伏立康唑对血液恶性肿瘤患者 CYP3A 活性的影响。
Xenobiotica. 2021 Oct;51(10):1199-1206. doi: 10.1080/00498254.2021.1969481. Epub 2021 Aug 24.
10
Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.CYP2C19基因多态性对伏立康唑在健康志愿者单次及多次给药后药代动力学的影响。
J Clin Pharmacol. 2012 Feb;52(2):195-203. doi: 10.1177/0091270010395510.

引用本文的文献

1
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole.炎症改变了接受伏立康唑治疗的患者中 CYP2C19 基因型和 CYP2C19 活性之间的相关性。
Clin Transl Sci. 2024 Jul;17(7):e13887. doi: 10.1111/cts.13887.
2
Cannabis Pharmacogenomics: A Path to Personalized Medicine.大麻药物基因组学：通往个性化医疗之路。
Curr Issues Mol Biol. 2023 Apr 17;45(4):3479-3514. doi: 10.3390/cimb45040228.
3
Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis.肺曲霉病中痰液伏立康唑的治疗药物监测
Pharmaceutics. 2022 Jul 30;14(8):1598. doi: 10.3390/pharmaceutics14081598.
4
Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.免疫功能低下儿童侵袭性曲霉菌病治疗面临的挑战。
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0215621. doi: 10.1128/aac.02156-21. Epub 2022 Jun 29.
5
External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy.中国血液恶性肿瘤成年患者伏立康唑群体药代动力学模型的外部评估。
Eur J Clin Pharmacol. 2022 Sep;78(9):1447-1457. doi: 10.1007/s00228-022-03359-2. Epub 2022 Jun 28.
6
CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.CYP2C19 表型与体质量指导下的伏立康唑在造血干细胞移植后婴儿和儿童中的起始剂量。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0062321. doi: 10.1128/AAC.00623-21.
7
Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data.炎症与药物基因组学变异对伏立康唑谷浓度的联合影响：个体数据的荟萃分析
J Clin Med. 2021 May 13;10(10):2089. doi: 10.3390/jcm10102089.
8
Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017.2014 年至 2017 年间，通过欧洲药品管理局在药物上市许可申请中的药物遗传药理学-药物动力学相互作用。
Clin Pharmacol Ther. 2020 Aug;108(2):338-349. doi: 10.1002/cpt.1834. Epub 2020 Apr 23.
9
Voriconazole: A Review of Population Pharmacokinetic Analyses.伏立康唑：群体药代动力学分析综述。
Clin Pharmacokinet. 2019 Jun;58(6):687-703. doi: 10.1007/s40262-019-00735-7.